IL243011A0 - An improved process for the production of monoclonal antibodies - Google Patents

An improved process for the production of monoclonal antibodies

Info

Publication number
IL243011A0
IL243011A0 IL243011A IL24301115A IL243011A0 IL 243011 A0 IL243011 A0 IL 243011A0 IL 243011 A IL243011 A IL 243011A IL 24301115 A IL24301115 A IL 24301115A IL 243011 A0 IL243011 A0 IL 243011A0
Authority
IL
Israel
Prior art keywords
production
monoclonal antibodies
improved process
improved
monoclonal
Prior art date
Application number
IL243011A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of IL243011A0 publication Critical patent/IL243011A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL243011A 2013-07-06 2015-12-21 An improved process for the production of monoclonal antibodies IL243011A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07
PCT/IN2014/000450 WO2015004679A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies

Publications (1)

Publication Number Publication Date
IL243011A0 true IL243011A0 (en) 2016-03-31

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243011A IL243011A0 (en) 2013-07-06 2015-12-21 An improved process for the production of monoclonal antibodies

Country Status (18)

Country Link
US (1) US20160215319A1 (enExample)
EP (1) EP3019528A1 (enExample)
JP (1) JP2016526385A (enExample)
CN (1) CN105431454A (enExample)
AR (1) AR096839A1 (enExample)
AU (1) AU2014288811B2 (enExample)
BR (1) BR112015032800A2 (enExample)
CA (1) CA2917484A1 (enExample)
EA (1) EA201690171A1 (enExample)
HK (1) HK1218297A1 (enExample)
IL (1) IL243011A0 (enExample)
IN (1) IN2013MU02285A (enExample)
MX (1) MX2016000123A (enExample)
NZ (1) NZ715246A (enExample)
SG (1) SG11201510342VA (enExample)
TW (1) TW201514305A (enExample)
WO (1) WO2015004679A1 (enExample)
ZA (1) ZA201509334B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) * 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
KR102682066B1 (ko) * 2021-10-12 2024-07-05 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법
IL328989A (en) * 2024-01-23 2026-08-01 Amgen Inc Methods for cargo variant modulation of monoclonal antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
MX355650B (es) * 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
US9045536B2 (en) * 2009-12-23 2015-06-02 Merck Sharp & Dohme Corp. Cell line 3M
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
LT2563906T (lt) * 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity

Also Published As

Publication number Publication date
BR112015032800A2 (pt) 2017-07-25
TW201514305A (zh) 2015-04-16
HK1218297A1 (zh) 2017-02-10
AU2014288811B2 (en) 2017-06-08
EA201690171A1 (ru) 2016-06-30
JP2016526385A (ja) 2016-09-05
SG11201510342VA (en) 2016-01-28
AU2014288811A1 (en) 2016-01-28
US20160215319A1 (en) 2016-07-28
AR096839A1 (es) 2016-02-03
WO2015004679A1 (en) 2015-01-15
CN105431454A (zh) 2016-03-23
EP3019528A1 (en) 2016-05-18
IN2013MU02285A (enExample) 2015-06-19
NZ715246A (en) 2017-07-28
ZA201509334B (en) 2017-03-29
MX2016000123A (es) 2016-07-14
CA2917484A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
ZA201509334B (en) Improved process for production of monoclonal antibodies
IL242649A (en) Purification process of monoclonal antibody
ZA201603433B (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HUE046414T2 (hu) Eljárás tagatóz elõállítására
IL242408B (en) A continuous multistep step for antibody purification
IL242695B (en) Device for the production of molybdenum-99
PL3074360T3 (pl) Sposób wytwarzania cementu portlandzkiego
ZA201506568B (en) Anti-tnf-anti-il-17 bispecific antibodies
EP2995679A4 (en) PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES
IL239737A0 (en) Method for protein production
EP3000803A4 (en) PROCESS FOR PREPARING DIAMINO-DICYCLOHEXYL-METHANE
SG11201507727VA (en) Process for the manufacture of polypropylene
IL240753A0 (en) Antibody purification methods
IL239689A0 (en) A method for producing antibodies
SI3027634T1 (sl) Proces za pripravo tulatromicina
EP2952895A4 (en) PROCESS FOR PRODUCING A MARKED ANTIBODY
EP2957543A4 (en) PROCESS FOR THE PREPARATION OF TRICHLOROSILANE
IL245474A0 (en) Process for the preparation of 5-fluoro-1h-pyrazoles
EP2978498A4 (en) PROTEIN PRODUCTION PROCESS
IL241779A (en) Method for protein production
PL2967095T3 (pl) Sposób wytwarzania serów o zmienionej strukturze
EP3029145A4 (en) PROCESS FOR PREPARING METHACRYLYL COA
IL229326A (en) Process for making n-iodine-affluent
ZA201603839B (en) Process for the production of synthesis gas
GB201301384D0 (en) Method for antibody production